MR Spectroscopy for 2HG for the prognosis of Glioma - Are we ready for the clinic yet?
| Saturday, November 16, 2024 |
| 2:40 PM - 3:00 PM |
| Panorama Room, Adelaide Convention Centre |
Overview
Angela Walls, South Australian Health and Medical Research Institute (SAHMRI) / Jones Radiology
Speaker
Ms Angela Walls
South Australian Health and Medical Research Institute (SAHMRI) / Jones Radiology
MR Spectroscopy for 2HG for the prognosis of Glioma - Are we ready for the clinic yet?
Presentation description
2-Hydroxyglutarate (2HG) Magnetic Resonance Spectroscopy (MRS) is an advanced imaging technique used to detect and measure the presence of 2HG, a metabolite linked to mutations in isocitrate dehydrogenase (IDH) enzymes. These mutations are common in gliomas, and the presence of IDH mutations generally indicates a better prognosis and longer overall survival compared to (non-mutated) IDH-wildtype gliomas. This talk explains the MRS methods for detecting 2HG, processing this data and asks the question, can this MRS be reliably done in our clinics, are we patient ready?
Biography
Angela is the Chief Technologist at the Clinical and Research Imaging Centre, a Jones Radiology clinic and afiliated with SAHMRI, South Australia's Health and Medical Research Institute. She is also a Fellow of the National Imaging Facility. She supports both national and international researchers through the planning and development of preclinical imaging projects through to translational research, with a primary focus on advanced Neurologic and Cardiac work.
Moderators
Jacob Cameron
MRI Technologist
Pacific Radiology ISMRT NZ President
Kate Negus
MRI Supervisor
Barwon Health
